PI3Kinasep110beta抗体—艾普蒂

+ +

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     Western blot analysis of PI3 Kinase p110 beta expression in (1) 293 cell lysate; (2) Mouse Brain lysate.    

  
  

The PI3K p110β antibody is a crucial tool for studying the class IA phosphatidylinositol 3-kinase (PI3K) isoform p110β, encoded by the *PIK3CB* gene. PI3Ks regulate cell growth, survival, and metabolism by generating lipid secondary messengers. Unlike the ubiquitously expressed p110α isoform, p110β plays distinct roles in signaling, particularly in PTEN-deficient cancers where it drives tumor progression independently of upstream receptor tyrosine kinase activation. Its unique ability to interact with G-protein-coupled receptors (GPCRs) and small GTPases further underscores its functional specialization.

Antibodies targeting p110β are widely used to assess its expression, subcellular localization, and activation status in cancer research, drug development, and mechanistic studies. They enable detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Specificity is critical, as p110β shares structural homology with other PI3K isoforms (e.g., p110α), necessitating rigorous validation to avoid cross-reactivity.

Research using these antibodies has highlighted p110β's therapeutic relevance, particularly in cancers resistant to p110α-targeted therapies. Inhibitors selective for p110β are under investigation, emphasizing the antibody's role in biomarker analysis and preclinical validation. Additionally, studies leveraging p110β antibodies have elucidated its non-catalytic functions in cell migration and cytoskeletal remodeling.

Overall, p110β antibodies are indispensable for dissecting PI3K signaling complexity and advancing targeted cancer therapies.